Celyad Oncology announces intention to terminate SEC reporting obligations
February 08, 2024 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the...
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
January 16, 2024 16:01 ET
|
Celyad Oncology SA
Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
December 20, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces, in accordance with Article 14 of the Belgian...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
December 15, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK) Limited...
Celyad announces management change
December 04, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD), a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of...
Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
December 01, 2023 06:42 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2023 (GLOBE NEWSWIRE) -- regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with...
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
November 21, 2023 16:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
November 14, 2023 16:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on...
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
November 09, 2023 01:00 ET
|
Celyad Oncology SA
Publication of data detailing the development of our microRNA (miRNA)-based multiplex shRNA approach, which allows to down-regulate several genes simultaneously, in Molecular Therapy – Nucleic...
Celyad Oncology announces the termination of its American Depository Receipt program
September 25, 2023 16:01 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces that Citibank, N.A., as depositary...